PharmaJet said today it inked a global license agreement with South Korean bioptherapeutics company Genexine to develop and commercialize DNA vaccines using PharmaJet’s needle-free injection system.
Through the deal, Genexine will gain access to use both the PharmaJet Stratis and Tropis devices for their Phase I and Phase IIa human clinical studies. The deal also includes a provision for a possible expansion into Phase III clinical trials and commercialization.
Read the whole story on our sister site, Drug Delivery Business
The post PharmaJet, Genexine ink deal for needle-free vaccine development appeared first on MassDevice.
from MassDevice http://ift.tt/2C8BVCI
Cap comentari:
Publica un comentari a l'entrada